CN107683139A - 用于治疗b细胞恶性肿瘤的赛度替尼 - Google Patents

用于治疗b细胞恶性肿瘤的赛度替尼 Download PDF

Info

Publication number
CN107683139A
CN107683139A CN201680035029.0A CN201680035029A CN107683139A CN 107683139 A CN107683139 A CN 107683139A CN 201680035029 A CN201680035029 A CN 201680035029A CN 107683139 A CN107683139 A CN 107683139A
Authority
CN
China
Prior art keywords
patient
buddhist nun
pharmaceutically acceptable
mutation
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680035029.0A
Other languages
English (en)
Chinese (zh)
Inventor
安加利·潘迪
格雷戈里·科菲
珍妮特·利兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Portola Pharmaceuticals LLC
Original Assignee
Portola Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharmaceuticals LLC filed Critical Portola Pharmaceuticals LLC
Publication of CN107683139A publication Critical patent/CN107683139A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201680035029.0A 2015-05-29 2016-05-27 用于治疗b细胞恶性肿瘤的赛度替尼 Pending CN107683139A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562168530P 2015-05-29 2015-05-29
US62/168,530 2015-05-29
US201562263582P 2015-12-04 2015-12-04
US62/263,582 2015-12-04
PCT/US2016/034861 WO2016196385A1 (en) 2015-05-29 2016-05-27 Cerdulatinib for the treatment of b-cell malignancies

Publications (1)

Publication Number Publication Date
CN107683139A true CN107683139A (zh) 2018-02-09

Family

ID=57441822

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680035029.0A Pending CN107683139A (zh) 2015-05-29 2016-05-27 用于治疗b细胞恶性肿瘤的赛度替尼

Country Status (9)

Country Link
US (2) US20180147203A1 (enExample)
EP (1) EP3302485B1 (enExample)
JP (2) JP7258462B2 (enExample)
KR (1) KR102613106B1 (enExample)
CN (1) CN107683139A (enExample)
AU (1) AU2016270658B2 (enExample)
CA (1) CA2987324C (enExample)
ES (1) ES2958412T3 (enExample)
WO (1) WO2016196385A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112074271A (zh) * 2018-05-04 2020-12-11 博尔托拉制药公司 用于治疗淋巴瘤的方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2913119T3 (es) 2015-08-12 2022-05-31 Portola Pharm Inc Cerdulatinib para tratar mieloma
WO2017096303A2 (en) 2015-12-04 2017-06-08 Portola Pharmaceuticals, Inc. Cerdulatinib for treating hematological cancers
US20180065317A1 (en) 2016-09-06 2018-03-08 Cc3D Llc Additive manufacturing system having in-situ fiber splicing
WO2018189566A1 (en) * 2017-04-10 2018-10-18 Dorian Bevec Use of a chemical compound as a therapeutic agent
JP7343526B2 (ja) 2018-05-04 2023-09-12 ポートラ ファーマシューティカルズ， エルエルシー セルデュラチニブの合成
JP7324778B2 (ja) 2018-05-04 2023-08-10 ポートラ ファーマシューティカルズ， エルエルシー セルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）の固体形態
CN108743947B (zh) * 2018-07-04 2020-12-15 复旦大学附属肿瘤医院 一种治疗b细胞淋巴瘤的药物组合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60255756A (ja) 1984-06-01 1985-12-17 Ikeda Mohandou:Kk アミノアルキルフエノキシ誘導体
WO1995032963A1 (en) 1994-06-01 1995-12-07 Yoshitomi Pharmaceutical Industries, Ltd. Thienylazole compound and thienotriazolodiazepine compound
ATE401312T1 (de) 1997-12-15 2008-08-15 Astellas Pharma Inc Pyrimidin-5-carboxamid-derivate
WO2003037352A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. 1-phenyl-5-n-heterocyclyl-pyrazoles as cyclooxygenase inhibitors for the treatment of inflammation associated disorders
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2004002964A1 (ja) 2002-06-28 2004-01-08 Yamanouchi Pharmaceutical Co., Ltd. ジアミノピリミジンカルボキサミド誘導体
JP2009544592A (ja) 2006-07-21 2009-12-17 ノバルティス アクチエンゲゼルシャフト Ｊａｋキナーゼ阻害剤としての２，４−ジ（アリールアミノ）−ピリミジン−５−カルボキサミド化合物
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
CN102066340B (zh) 2008-04-16 2014-05-14 波托拉医药品公司 作为syk或jak蛋白激酶抑制剂的2,6-二氨基-嘧啶-5-基甲酰胺类化合物
US8367689B2 (en) 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
WO2012045020A1 (en) 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine
HK1198579A1 (en) * 2011-08-10 2015-04-30 Novartis Pharma Ag Jak p13k/mtor combination therapy
KR20150036034A (ko) 2012-06-27 2015-04-07 노보머, 인코포레이티드 폴리에스터 제조를 위한 촉매 및 방법
BR112015001690A2 (pt) * 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
EP2903970A4 (en) 2012-10-08 2016-11-30 Portola Pharm Inc SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
CN111329989A (zh) 2012-11-02 2020-06-26 药品循环有限责任公司 Tec家族激酶抑制剂辅助疗法
CN105282602A (zh) * 2014-07-07 2016-01-27 乐视致新电子科技（天津）有限公司 数据处理方法、装置及移动终端设备
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
ES2913119T3 (es) 2015-08-12 2022-05-31 Portola Pharm Inc Cerdulatinib para tratar mieloma
WO2017096303A2 (en) 2015-12-04 2017-06-08 Portola Pharmaceuticals, Inc. Cerdulatinib for treating hematological cancers

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112074271A (zh) * 2018-05-04 2020-12-11 博尔托拉制药公司 用于治疗淋巴瘤的方法
CN112074271B (zh) * 2018-05-04 2023-10-20 博尔托拉制药公司 用于治疗淋巴瘤的方法

Also Published As

Publication number Publication date
KR102613106B1 (ko) 2023-12-12
KR20180011210A (ko) 2018-01-31
CA2987324A1 (en) 2016-12-08
EP3302485B1 (en) 2023-07-12
CA2987324C (en) 2023-08-22
US12350269B2 (en) 2025-07-08
US20220096471A1 (en) 2022-03-31
ES2958412T3 (es) 2024-02-08
WO2016196385A1 (en) 2016-12-08
AU2016270658B2 (en) 2021-08-12
AU2016270658A1 (en) 2018-01-04
EP3302485A4 (en) 2019-02-27
JP2021152076A (ja) 2021-09-30
US20180147203A1 (en) 2018-05-31
JP7258462B2 (ja) 2023-04-17
EP3302485A1 (en) 2018-04-11
JP2018520117A (ja) 2018-07-26

Similar Documents

Publication Publication Date Title
US12350269B2 (en) Cerdulatinib for the treatment of b-cell malignancies
US11446300B2 (en) Cerdulatinib for treating hematological cancers
JP2022017495A (ja) 癌を治療するための併用療法
BR112019017851A2 (pt) método para tratar câncer em um indivíduo que precisa do mesmo, método para identificar um indivíduo que tem um câncer como um candidato para o tratamento com um antagonista de smarca2, método para identificar uma célula cancerosa como sensível ao tratamento com um antagonista de smarca2, antagonista de smarca2 para uso no tratamento de câncer em um indivíduo que precisa do mesmo, antagonista de smarca2 para uso como um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo e uso do antagonista de smarca2 na fabricação de um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo
CN112074271B (zh) 用于治疗淋巴瘤的方法
CN106659716A (zh) 阿吡莫德组合物及其使用方法
CN108025076A (zh) 使用阿吡莫德治疗癌症的方法
JP2019511204A (ja) コパンリシブバイオマーカー
WO2019109074A1 (en) Mebendazole cancer therapies and methods of use
JP2019512003A (ja) コパンリシブバイオマーカー
WO2020132259A1 (en) Compositions and methods of treating cancers by administering a phenothiazine-related drug that activates protein phosphatase 2a (pp2a)
HK1253804B (en) Cerdulatinib for the treatment of b-cell malignancies
HK1253804A1 (en) Cerdulatinib for the treatment of b-cell malignancies
HK1262118B (en) Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma
HK1262118A1 (en) Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma
HK40061501A (en) Combination therapy for treating cancer
TW202123929A (zh) 治療癌症之方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20180209

RJ01 Rejection of invention patent application after publication